SCHEMBL20096902

SCHEMBL20096902

COc1cccc(CN2CCC3(Cc4cccc(C(=O)NO)c4C3)C2=O)c1

nearest known ligand 0.80

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC11 Q96DB2 13/20 0.80
HDAC1 Q13547 3/20 0.46
HDAC6 Q9UBN7 3/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46
HDAC5 Q9UQL6 1/20 0.46
MMP1 P03956 1/20 0.42
MMP9 P14780 1/20 0.42
MMP13 P45452 1/20 0.42
ADAM17 P78536 1/20 0.42
PKM P14618 1/20 0.42
DRD4 P21917 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20096901 0.94 HDAC11 (0.74) HDAC11HDAC1HDAC6HDAC8HDAC3
SCHEMBL20096905 0.92 HDAC11 (0.78) HDAC11HDAC1HDAC6MMP1MMP13
SCHEMBL20096917 0.89 HDAC11 (0.72) HDAC11HDAC6DRD4
SCHEMBL20096740 0.89 HDAC11 (1.00) HDAC11HDAC1HDAC6HDAC8HDAC3
SCHEMBL20096852 0.88 HDAC11 (0.81) HDAC11HDAC1HDAC6HDAC8HDAC3
SCHEMBL20096922 0.87 HDAC11 (0.83) HDAC11HDAC1HDAC6HDAC7
SCHEMBL20096483 0.87 HDAC11 (0.79) HDAC11HDAC1HDAC6HDAC8
SCHEMBL20096467 0.87 HDAC11 (0.82) HDAC11HDAC1HDAC6HDAC7
SCHEMBL20096900 0.86 HDAC11 (0.78) HDAC11HDAC1HDAC6HDAC8HDAC4
SCHEMBL20096910 0.86 HDAC11 (1.00) HDAC11HDAC1HDAC6HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345672-B2 Methods using HDAC11 inhibitors VALO HEALTH, INC. (US) 2022-05-31 US disclosed
US-20190084946-A1 METHODS USING HDAC11 INHIBITORS Valo Health, LLC 2019-03-21 US disclosed
US-20190084945-A1 METHODS USING HDAC11 INHIBITORS VALO HEALTH, INC. 2019-03-21 US disclosed
US-20180127386-A1 METHODS USING HDAC11 INHIBITORS VALO EARLY DISCOVERY, INC. 2018-05-10 US disclosed
WO-2018075959-A1 METHODS USING HDAC11 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2018-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345672-B2 Methods using HDAC11 inhibitors HDAC11, HDAC1, HDAC10 HDAC11 1/4885HDAC1 2/4885HDAC6 6/4885
US-20180127386-A1 METHODS USING HDAC11 INHIBITORS HDAC11, HDAC1, HDAC10 HDAC11 1/4885HDAC1 2/4885HDAC6 6/4885
US-20190084945-A1 METHODS USING HDAC11 INHIBITORS HDAC11, HDAC1, HDAC10 HDAC11 1/4885HDAC1 2/4885HDAC6 6/4885
US-20190084946-A1 METHODS USING HDAC11 INHIBITORS HDAC11, HDAC1, HDAC10 HDAC11 1/4885HDAC1 2/4885HDAC6 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.